Inventor
HALE JEFFREY J
US35 patents
⚠️ This page may combine multiple inventors who share the name “HALE JEFFREY J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK & CO INC
22 patentsUS5719147AFeb 17, 1998
Morpholine and thiomorpholine tachykinin receptor antagonists
MERCK & CO INC193 citations99
US5691336ANov 25, 1997
Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
MERCK & CO INC154 citations99
US6166037ADec 26, 2000
Pyrrolidine and piperidine modulators of chemokine receptor activity
MERCK & CO INC171 citations97
US5780467AJul 14, 1998
Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
MERCK & CO INC60 citations96
US5716942AFeb 10, 1998
Treatment of migraine with morpholine tachykinin receptor antagonists
MERCK & CO INC39 citations96
US5637699AJun 10, 1997
Process for preparing morpholine tachykinin receptor antagonists
MERCK & CO INC85 citations96
US5512570AApr 30, 1996
Treatment of emesis with morpholine tachykinin receptor antagonists
MERCK & CO INC43 citations96
US7351725B2Apr 1, 2008
N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
MERCK & CO INC40 citations93
US6235735B1May 22, 2001
Morpholine and thiomorpholine tachykinin receptor antagonists
MERCK & CO INC19 citations93
US6048859AApr 11, 2000
Morpholine and thiomorpholine tachykinin receptor antagonists
MERCK & CO INC26 citations93
US5869496AFeb 9, 1999
Spiro-substituted azacycles as tachykinin receptor antagonists
MERCK & CO INC37 citations92
US7309721B2Dec 18, 2007
Aminoalkylphosphonates and related compounds as Edg receptor agonists
MERCK & CO INC37 citations91
US7605171B2Oct 20, 2009
(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
MERCK & CO INC27 citations90
US7479504B2Jan 20, 2009
Edg receptor agonists
MERCK & CO INC28 citations90
US7220734B2May 22, 2007
1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists
MERCK & CO INC19 citations84
US5591737AJan 7, 1997
Substituted azetidinones as anti-inflammatory and antidegenerative agents
MERCK & CO INC18 citations84
US7199142B2Apr 3, 2007
1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
MERCK & CO INC21 citations83
US5922706AJul 13, 1999
Morpholine and thiomorpholine tachykinin receptor antagonists
MERCK & CO INC6 citations74
US5872116AFeb 16, 1999
Morpholine and thiomorpholine tachykinin receptor antagonists
MERCK & CO INC14 citations74
US6638930B2Oct 28, 2003
Morpholine and thiomorpholine tachykinin receptor antagonists
MERCK & CO INC1 citations63
US5391819AFeb 21, 1995
Process of making chiral 2-aryl-1,4-butanediamine derivatives as useful neurokinin-A antagonists
MERCK & CO INC0 citations52
US7125887B2Oct 24, 2006
Pyrrolidine modulators of CCR5 chemokine receptor activity
MERCK & CO INC1 citations49
MERCK SHARP & DOHME
5 patentsUS7906652B2Mar 15, 2011
Heterocycle-substituted 3-alkyl azetidine derivatives
MERCK SHARP & DOHME8 citations84
US7999107B2Aug 16, 2011
Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
MERCK SHARP & DOHME13 citations83
US8354403B2Jan 15, 2013
Pyrrolidine derived beta 3 adrenergic receptor agonists
MERCK SHARP & DOHME15 citations82
US8372863B2Feb 12, 2013
Tetrahydro-1H-pyrrolo fused pyridones
MERCK SHARP & DOHME4 citations62
US8372857B2Feb 12, 2013
Substituted 4-hydroxypyrimidine-5-carboxamides
MERCK SHARP & DOHME0 citations39